We recently compiled a list of the 12 Best Technology Stocks to Invest In for the Long Term. In this article, we are going to ...

TCS Q3 results 2025 are likely to be muted with a marginal rise in net profit and flat revenue growth on a sequential basis.

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses.

I believe quality analysis particularly in the tech sector can be hard to find. I highlight top calls from my firm's Forbes ...

We recently published a list of 10 Best Single Digit Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Single Digit Stocks To Buy Now. In this article, we are going to take a look at where ...

Dexterra's Q3 2024 results show revenue increase, dividend declaration, stock buyback, and potential for acquisitions. Click ...

State-run renewable energy financier Indian Renewable Energy Development Agency (IREDA) on Thursday (January 9) reported a 26 ...

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis ("UC”) reaches 1,003 of 1,224 ...

Retailer says its third-quarter net income totalled $74.1-million compared with about $43.1-million a year earlier ...

Ahead of the Q3 results today, the PSU stock was trading marginally lower. IREDA shares have given multibagger returns of ...